What is SYNVISC®/Synvisc-One®?
- SYNVISC® and Synvisc-One® are viscosupplements that achieve their therapeutic effects by restoring the physiological and rheological state of the arthritic joint tissues
- They are viscosupplements that are biologically similar to hyaluronan. Hyaluronan is a component of synovial fluid that is responsible for its viscoelasticity. Synovial fluid lubricates the joint and acts as a shock absorber.
- Demonstrated efficacy to help your patients ease OA-related pain and discomfort and allow for more extensive movement of the joint
- Prospective clinical data in patients with OA of the knee have shown the benefit of the treatment for up to 52 weeks following a single course of three SYNVISC® injections
- SYNVISC®/Synvisc-One® treatment can be repeated according to the recommended dosage regimens. Please speak with your doctor.
SYNVISC® and Synvisc-One® (hylan G-F 20) are intra-articular viscosupplement injections that provide your patients long-lasting relief from OA-related pain and discomfort
Used to manage OA for over 30 years in Canada
SYNVISC®/Synvisc-One® are the most widely used viscosupplements across Canada
20+ million knees treated worldwide
The OnTRACK patient program celebrated 10 years of supporting patients in 2023
 |
OnTRACK is a complimentary program available to all your SYNVISC®/Synvisc-One® patients, designed to support them through their OA journey |
SYNVISC® reduces OA-related pain and discomfort in the knee, hip, shoulder and ankle, with a recommended treatment regimen of 1–3 injections depending on the joint treated.
- The injection may be repeated 6 months after the first injection, if warranted by the patient’s symptoms
- The maximum recommended dosage of SYNVISC® depends on the joint being treated. Please refer to the Instructions for Use for further information.
 |
 |
 |
 |
Synvisc-One® reduces OA-related pain and discomfort of the knee, with a recommended treatment regimen of 1 injection.
- Synvisc-One® injections can be repeated with a minimum of six months between treatment regimens if needed
|
SYNVISC® is used in the knee, hip, ankle and shoulder while Synvisc-One® is used in the knee joint.
With SYNVISC®, the duration of effect for those patients who respond to treatment has generally been reported up to 26 weeks. However, prospective clinical data in patients with OA of the knee have shown benefit of treatment up to 52 weeks, following a single course of three SYNVISC® injections.*
Prospective clinical data in patients with OA of the knee have shown benefit of treatment up to 26 weeks following a single Synvisc-One® injection.*
Patients are supported beyond your clinic through the exclusive OnTRACK program.
Speak to your patients about OA
It has been estimated that 59–87% of adults with OA have at least one other significant chronic (long-term) disease, with the most common being:
- Cardiovascular disease
- Hypertension
- Diabetes mellitus
OA can affect younger adults too. Talk to your patients about recognizing the early signs of the disease.
Help your patients manage OA pain! SYNVISC®/Synvisc-One® is indicated in all stages of joint pathology.
You are part of the solution!
SYNVISC®/Synvisc-One® is your partner in the fight against OA and would like to help your OA program.
Get direct access
To order SYNVISC®/Synvisc-One® and/or request further information, including patient education materials, please call 1-800-796-7991.
Learn more about the OnTRACK program – a comprehensive support program exclusively designed for your SYNVISC®/Synvisc-One® patients.
For more information, please call 1-800-796-7991.
Become an injection centre
Are you already offering patients viscosupplementation injections and looking for more patients?
We'd like to help patients find you! Contact us to find out how we can help.
* Each person responds differently to treatment and will experience different relief.
Home > Healthcare professionals